Virtual dietitian visits tested to fight weight loss in stomach cancer
NCT ID NCT06497569
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a program called STRONG that provides remote dietitian visits and food tracking for people with gastroesophageal cancer. The goal is to see if this approach is practical and helps reduce malnutrition compared to usual care. About 80 participants will receive nutrition counseling via video calls and use an app to log meals.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Dietitian consultation and nutrition guidance via telehealth
- What this could lead to
- If successful, this could show that remote nutrition support helps cancer patients maintain weight and strength during treatment, potentially reducing malnutrition.
- What could go wrong
- This is a small feasibility study (80 people) testing if the program is practical, not whether it works. It may not show clear benefits or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2024
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants must be 18 years of age or older * Participants must have locally advanced or metastatic gastroesophageal cancer (GEC) * Participants must plan to initiate chemotherapy and/or radiation therapy with a plan to have surgery or definitive treatment follow up at Moffitt * Participants must be able to speak and read Spanish and/or English * Participants must be able to provide informed consent Exclusion Criteria: * Participants have a documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g. severe dementia) * Use of feeding tubes at the time of study enrollment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastroesophageal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
UNC Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a new drug DM001 take on advanced solid tumors?
- Can a targeted therapy tame hard-to-treat stomach and esophageal cancers?
- Can focused radiation boost Immunotherapy's power against advanced cancer?
- Pulsing radiation may spare esophageal cancer patients from agonizing throat pain
- Can sequencing immunotherapy before chemo boost stomach cancer outcomes?